Article
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2020
von Mehren Margaret, George Suzanne, Heinrich Michael C, Schuetze Scott M, Yap Jeffrey T, Yu Jain Q, Abbott Amanda, Litwin Samuel, Crowley John, Belinsky Martin, Janeway Katherine A, Hornick Jason L, Flieder Douglas B, Chugh Rashmi, Rink Lori, Van den Abbeele Annick D
Abstract excerpt
PURPOSE: Most gastrointestinal stromal tumors (GIST) have activating mutations of KIT, PDGFRA, or uncommonly BRAF. Fifteen percent of adult and 85% of pediatric GISTs are wild type (WT), commonly having high expression of IGF-1R and loss of succinate dehydrogenase (SDH) complex function. We tested the efficacy of linsitinib, an oral TKI IGF-1R inhibitor, in patients with WT GIST. PATIENTS AND METHODS: A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.